This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Escitalopram Treatment for Depressive Disorder Following Acute Coronary Syndrome: A 24-Week Double-Blind, Placebo-Controlled Trial

Jae-Min Kim, MD, PhD; Kyung-Yeol Bae, MD, PhD; Robert Stewart, MD, MRCPsych; Bo-Ok Jung, MD, MSc; Hee-Ju Kang, MD, MSc; Sung-Wan Kim, MD, PhD; Il-Seon Shin, MD, PhD; Young Joon Hong, MD, PhD; Ju Han Kim, MD, PhD; Hee-Young Shin, MD, PhD; Gaeun Kang, MD, MSc; Youngkeun Ahn, MD, PhD; Jong-Keun Kim, MD, PhD; Myung Ho Jeong, MD, PhD; and Jin-Sang Yoon, MD, PhD

Published: October 14, 2014

Article Abstract

Objective: Depression is common after acute coronary syndrome (ACS) and has adverse effects on prognosis. There are few evidence-based interventions for treating depression in ACS. This study investigated the efficacy and safety of escitalopram in treating depressive disorders identified 2-14 weeks after a confirmed ACS episode.

Method: A total of 217 patients with DSM-IV depressive disorders (121 major and 96 minor) and ACS were randomly assigned to receive escitalopram in flexible doses of 5-20 mg/d (n = 108) or placebo (n = 109) for 24 weeks. The study was conducted from 2007 to 2013. The primary outcome measure was the Hamilton Depression Rating Scale (HDRS). Secondary outcome measures included the Montgomery-Asberg Depression Rating Scale (MADRS), Beck Depression Inventory (BDI), Clinical Global Impressions-Severity of Illness scale (CGI-S), Social and Occupational Functioning Assessment Scale (SOFAS), and World Health Organization Disability Assessment Schedule-12. Cardiovascular safety outcomes included echocardiography, electrocardiography, laboratory test, body weight, and blood pressure results.

Results: Escitalopram was superior to placebo in reducing HDRS scores (mean difference = 2.3, P = .016, effect size = 0.38). Escitalopram was also superior to placebo in decreasing depressive symptoms evaluated by the MADRS, BDI, and CGI-S and in improving SOFAS functioning level. Escitalopram was not associated with any harmful changes in cardiovascular safety measures. Dizziness was significantly more frequently reported in the escitalopram group (P = .018), but there were no significant differences in any other adverse events.

Conclusions: These results indicate that escitalopram has clinically meaningful antidepressant effects with no evidence of reduced cardiovascular safety in depressive disorder following ACS.

Trial Registration: ClinicalTrials.gov identifier: NCT00419471

Volume: 76

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Telehealth of Coordinated Specialty Care in Early Psychosis During COVID-19

As the COVID-19 pandemic emerged in 2020, access to in-person clinical care was restricted. This study explored...

Read More...